PharmaCyte Bio to prepare for pancreatic cancer product trial, shares up

Pharmacyte Biotech

13/04/2022 15:42

** Shares of drug developer  PMCB.O  rise 3.1% to $2.30 
    ** PMCB says it has decided to speed up preparations for the
mid-stage clinical trial of its CypCaps product in locally
advanced, inoperable pancreatic cancer  urn:newsml:reuters.com:*:nBw4JPTSka
    ** The U.S. FDA had put the company's application for the
trial on clinical hold in 2020
    ** Co says its plan is to prepare for patient enrollment now
so it can begin the trial almost immediately after the clinical
hold is lifted 
    ** Stock down 8% YTD

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))